Sanjeev Kumar

发表

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

R. Bernards, C. Caldas, Mariette Schrier, 2017 .

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

R. Bernards, C. Caldas, Mariette Schrier, 2019, Clinical Cancer Research.

Ovarian Cancer Detection: Cause, Symptoms and Techniques

Sanjeev Kumar, Anjali Sharma, Satnam Singh, 2015 .

Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes.

S. Kao, B. McCaughan, M. Boyer, 2017, Lung Cancer.

OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION

W. Gullick, D. Venter, Sanjeev Kumar, 1987, The Lancet.

Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic

E. Lim, Sanjeev Kumar, Allegra Freelander, 2021, Cancers.

Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancer

J. Carroll, R. Siersbæk, Sanjeev Kumar, 2018, Genes & development.

Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study

Keunchil Park, Y. Bang, Sang-We Kim, 2020, Targeted Oncology.

The role of chemotherapy and new targeted agents in the management of primary prostate cancer

S. Pacey, Sanjeev Kumar, 2016, Journal of clinical urology.

Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics

Shaomeng Wang, D. Bernard, Yujun Zhao, 2012 .

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

J. Shamash, P. Szlosarek, J. Spicer, 2020, JTO clinical and research reports.

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

Suzanne F. Jones, A. Oza, J. Cragun, 2021, Clinical Cancer Research.

Estrogen receptor positive breast cancer patient–derived xenograft models in translational research

D. Segara, N. Portman, E. Lim, 2020 .

Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India.

U. Batra, Sanjeev Kumar, D. Parmar, 2021, Clinical breast cancer.

Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer.

M. Suntharalingam, J. Rhee, F. Pericle, 2003, Archives of otolaryngology--head & neck surgery.

Pembrolizumab for the treatment of melanoma

C. McNeil, Sanjeev Kumar, 2015, Expert review of clinical pharmacology.

Real-world assessment of the effect of impact of tumor size on pathological complete response rates in triple negative breast cancer after neoadjuvant chemotherapy.

Sanjeev Kumar, S. Crocamo, B. D. de Paula, 2020, Chinese clinical oncology.

Abstract CT025: Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation

Suzanne F. Jones, A. Oza, L. Ottesen, 2019, Clinical Trials.

Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.

Suzanne F. Jones, D. Spigel, G. Falchook, 2019, Journal of Clinical Oncology.

Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.

Suzanne F. Jones, A. Oza, J. Cragun, 2019, Journal of Clinical Oncology.

A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

Suzanne F. Jones, Melissa L. Johnson, J. Sachdev, 2023, Investigational New Drugs.

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

Richard G. Moore, Jung-Min Lee, B. Slomovitz, 2020, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract CT012: Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts

Suzanne F. Jones, A. Tinker, A. Oza, 2019, Clinical Trials.

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

Suzanne F. Jones, A. Tinker, A. Oza, 2023, Targeted Oncology.

R. Bernards, C. Caldas, Mariette Schrier, 2019, Clinical Cancer Research.